After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Trade-Ideas LLC identified Gilead (GILD) as a post-market laggard candidate
Gilead's stock trades at a discount to other biotech peers because its drug research pipeline lacks the blockbusters needed to make up for slowing sales from its hepatitis C franchise.
Earnings reports will test the timeframe mettle for some investors and traders.
The biopharmaceutical giant is getting ready to report its second-quarter results, which are set to be released after Monday's close.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.